ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬CDEÏÔʾ£¬£¬£¬£¬£¬£¬ÓÀÌ©ÉúÎ↑·¢µÄÀ©Ôö»î»¯µÄÁܰÍϸ°û£¨°®¿ÉÂØÈü×¢ÉäÒº£©ÄâÄÉÈëÓÅÏÈÉóÆÀ£¬£¬£¬£¬£¬£¬ÓÃÓÚÔ·¢ÐÔ¸Îϸ°û°©¸ùÖÎÊõºó¸ß¸´·¢Î£º¦µÄ²¿·ÖÈËȺµÄÖÎÁÆ¡£¡£¡£
2. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬·¼ÍØÉúÎïÐû²¼Æä×ÔÖ÷Ñз¢µÄÖØ×éÏÙÏà¹Ø²¡¶¾£¨rAAV£©»ùÒòÖÎÁƺòÑ¡²úÆ·FT-003×¢ÉäÒºÔٴλñÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÌÇÄò²¡ÊÓÍøÄ¤²¡±ä£¨Diabetic Retinopathy£¬£¬£¬£¬£¬£¬DR£©¡£¡£¡£
3. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬CDEÍøÕ¾ÏÔʾ£¬£¬£¬£¬£¬£¬¿µÀÖÎÀÊ¿µÄÖØ×éÈý¼ÛÈËÈéÍ·Áö²¡¶¾£¨16/18/58ÐÍ£©ÒßÃ磨Èý¼ÛHPVÒßÃ磩ÄâÄÉÈëÓÅÏÈÉóÆÀ¡£¡£¡£
4. ¿ËÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬°ÙʱÃÀÊ©¹ó±¦¹«Ë¾É걨µÄ1ÀàÐÂÒ©BMS-986489£¨BMS-986012 + nivolumabÀο¿¼ÁÁ¿¸´·½£©×¢ÉäÒº»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬£¬Ä⿪·¢ÖÎÁÆÐ¡Ï¸°û·Î°©£¨SCLC£©»¼Õß¡£¡£¡£ÕâÊÇÒ»¿î¿¹Fucosyl-GM1µ¥¿¹BMS-986012Ó뿹PD-1µ¥¿¹ÄÉÎäÀûÓȵ¥¿¹µÄÀο¿¼ÁÁ¿×éºÏ¡£¡£¡£
1. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬Ó¢ÎùÖÇÄÜÐû²¼ÒÑÍê³ÉÓÉÑÇÖÞ×î´óµÄ×ÔÁ¦×ʲú¹ÜÀí¹«Ë¾Ö®Ò»»ÝÀí¼¯ÍÅ£¨HKG: 0806£©ÆìϵÄ˽ļ¹ÉȨ»ù½ð¡¢ÆÖ¶«´´Í¶ºÍÆÖ·¢¼¯ÍÅ¡¢Îý´´Í¶ºÍÒËÐ˹ú¿ØÁªºÏÁìͶµÄ1.1ÒÚÃÀÔªEÂÖÈÚ×Ê¡£¡£¡£
1. 3ÔÂ12ÈÕ£¬£¬£¬£¬£¬£¬Î¬ÂÞÄÉ´óѧVincenzo Corbo¡¢¸ñÀ˹¸ç´óѧPeter BaileyͨѶÔÚ¡¶Nature¡·½ÒÏþÂÛÎÄ¡°MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC¡±£¬£¬£¬£¬£¬£¬ÔÚÒÈÏÙ°©£¨PDAC£©Öз¢Ã÷ÁËȾɫÌåÍâ DNA£¨ecDNA£©µÄÖ÷Òª×÷Ó㬣¬£¬£¬£¬£¬ÎªÃ÷È·ÕâÖÖÖØ´ó¼²²¡´øÀ´ÁËеÄ˼Ð÷¡£¡£¡£
[1]Elena Fiorini et al., MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Nature (2025) Doi: https://doi.org/10.1038/s41586-025-08721-9
Ïà¹ØÐÂÎÅ